EntroGen, Inc. products

EntroGen RNA Fusion Gene Panel is a complete next generation sequencing (NGS) solution for detecting 307 clinically relevant fusions over 23 genes.

EntroGen NGS Targeted Hotspot Panel is a comprehensive pan-cancer assay designed to detect clinically relevant hotspot mutations in solid tumors.  Utilizing a robust next-generation sequencing (NGS) platform, labs are able to simultaneously analyze several different tumor types by batching up to 12 samples on a single run*.  NGS Targeted Hotspot Panel (THSP) is compatible with fresh frozen, and formalin fixed paraffin embedded (FFPE) samples. This assay features high sensitivity and throughput detecting clinically relevant hotspot variants down to 5% with minimal DNA input.  With its comprehensive, streamlined workflow, THSP is designed to be seamlessly integrated into any lab.  Laboratories with specific challenges, such as low disease specific sample volumes, are able to batch various sample types together and accelerate tumor profiling.

PIK3CA Mutations and CancerThe PIK3CA gene encodes the p110a subunit of phosphatidyl 3-kinase, a lipid kinase involved in cell growth, proliferation, motility and survival. It has a central role in the PI3K-AKT-mTOR pathway. Somatic mutations in the PIK3CA gene have been implicated in the pathogenesis of several cancers, including colon cancer, gliomas, gastric cancer, breast cancer, endometrial cancer, and lung cancer. PIK3CA mutations commonly occur in exon 9, which encodes the helical domain and exon 20, which encodes the kinase domain.

BRCA Complete Expanded Panel is a complete next generation sequencing (NGS) solution for detecting clinically relevant BRCA1 and BRCA2 mutations along with extended coverage of CHEK2, PALB2, RAD51C and TP53.

The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12, 13 and 61. Several studies have demonstrated that tumors carrying any of these mutant forms of the KRAS gene are less likely to respond to anti-EGFR antibody therapy.